Pear Therapeutics, Inc.
PEAR · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 201.7% | -55.2% | -71.2% | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 35.5% | -24.4% | 81.7% | 96.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,334.5% | -3,622.3% | -801.5% | -158.8% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -187% | -482.3% | -1,071.9% | 38.1% |
| EPS Diluted | -0.17 | -0.18 | -0.73 | 0.09 |
| % Growth | 5.6% | 75.3% | -912% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |